



# Pistoia Alliance

## Emerging Life Sciences Collaboration on Common Service Specification

Ian Harrow (Pfizer) and Nick Lynch (Astra Zeneca) for the Pistoia Alliance

ICIC 2010

26<sup>th</sup> Oct 2010

<http://pistoiaalliance.org>




# Pistoia Organisation



- Pistoia Organisation
- Four projects:-
  - Biomedical Knowledge Brokering SESL pilot
    - More depth on this
  - Vocabulary Standards Initiative
    - An emerging project
  - Sequence services
  - Electronic Lab Notebook
- Summary
- Acknowledgements

# Pistoia Background and History



## Pistoia Description

The primary purpose of the Pistoia Alliance is to streamline non-competitive elements of the life science workflow by the specification of common standards, business terms, relationships and processes

## Pistoia Goals

- to allow this framework to encompass/support most pre-competitive work between the organisations
- to support life science workflow prior to submission
- to work with other Standards organisations


## History

Initial Meeting with GSK, AZ, Pfizer and Novartis - outlined similar challenges and frustrations in the Informatics sector of Discovery

The advent of Web Services and Web 2.0 allow for decoupling of proprietary data from technology

Publicly available structural and biological DBs allow for a non-IP related analysis and as a scientific test suite.

Sponsorship from R&D IS heads within Life Science industry



# Pistoia Domains

## Pistoia Domains group areas of interest, scope and deliver projects

### Pistoia Groups – as defined in byelaws

Board of Directors

Officers  
(Operational Team)

Technical Committee

### Pistoia Domain – high level collection of Working Groups with common themes

Domain Steering Groups

Allows governance across a domain using Working Group chairs and Technical Committee reps

Working Groups

The main project delivery mechanism in Pistoia. All standards will be delivered by WGs

Pistoia Members

Provide expertise for WGs and running Pistoia Define:

- Requirements
- Technical Standards
- Service Standards

### External Groups outside of Pistoia

Could:

- Join Pistoia
- Influence Pistoia members
- Influence through other standards groups and activities
- Collaborate on standards' feasibility studies
- Collaborate through non-Pistoia Standards initiatives

# Pistoia Membership



Bristol-Myers Squibb Company




GGA Software Services LLC



# Pistoia Domains

Pistoia Domains focus on business workflows /supply chains





# The Pistoia SESL Project

## Pistoia Alliance SESL Pilot for a Biomedical Brokering Service

Ian Harrow, Wendy Filsell, Dietrich Rebholz Schuhmann

<http://pistoiaalliance.org>



# SESL: Biomedical Knowledge Brokering



- **Challenge:**

- No single system for retrieving gene to disease relationships contained in both published & biological database content
- Need a 'push model' for biomedical knowledge access: the current model requires the consumer to search 1000's of content sources

- **Opportunity: Pilot Project with key stakeholders**


- Pilot a 'push model' for biomedical knowledge brokering
- Engage multiple consumers, content providers and a single, public group to develop the necessary infrastructure to explore the standards required for the model to work in production

- **History:**


- May 2008: Common Disease Knowledge Environment (CDKE) IMI call drafted
- Sep 2008: postponed call publication
- Jan 2009: x-pharma meeting in London on how to progress CDKE
- Apr 2009: CDKE presented at SESL workshop
- Oct 2009: SESL Pilot meeting (funders)
- Jan 2010: Pilot launch



# The Knowledge Service Framework



# A Production Service vision...



# The Pilot



- **Deliverables:**

- Publication of standards & recommendations for service implementation
- Pilot implementation of service for a single disease (assertions from pre-defined document sets & databases)
- **Establish ways of working pre-competitively across industry/vendor/academia**
- Dialogue and assessment of cost / value, with key content suppliers in moving to such a push model for content (viability of moving to production)


- **Status:**

- AZ, Pfizer, GSK, Roche, Unilever, EBI, NPG, OUP, Elsevier & RSC
- 12 month project, £200K direct funding (+ PM & Architecture support)
- Contract between Pistoia & EBI signed 20<sup>th</sup> January 2010 for 1 year

- **Scope:**

- Development of an assertion database in combination with a user interface and associated web services for one disease/indication/phenotype of broad interest: **Type II Diabetes**
- Assertional content derived from 3 structured data sources and limited Journal content (co-occurrence & statistical derivation from full text)
- Assertional evidence for filtering and drill down to primary data.
- Limited vocabulary development for area of focus: **Type II Diabetes**

# Minimal configuration to test a Brokering Service



# SESL user interface mock-up

## SESL Results

	Gene	R'ship	Disease	Species	Evidence
1	<i>abc1</i>	<i>Co-occurs</i>	<i>Diabetes</i>	<i>Mus</i>	<u><i>Paper UID:1234</i></u>
2	<i>abc1</i>	<i>Up-Reg</i>	<i>Diabetes</i>	<i>Homo</i>	<u><i>ArrayExpress: XXX</i></u>
3	<i>abc2</i>	<i>Co-occurs</i>	<i>Diabetes</i>	<i>Homo</i>	<u><i>Paper UID:1344</i></u>
4	<i>abc13</i>	<i>Co-occurs</i>	<i>Diabetes</i>	<i>Mus</i>	<u><i>Paper UID:1314</i></u>
5	<i>abc7</i>	<i>Mutation</i>	<i>Diabetes</i>	<i>Rattus</i>	<u><i>OMIMI: XXX</i></u>
6	<i>abc1</i>	<i>Co-occurs</i>	<i>Diabetes</i>	<i>Mus</i>	<u><i>Paper UID:45643</i></u>
7	<i>abc1</i>	<i>Co-occurs</i>	<i>Diabetes</i>	<i>Homo</i>	<u><i>Paper UID:2143</i></u>
8	<i>abc1</i>	<i>Co-occurs</i>	<i>Diabetes</i>	<i>Mus</i>	<u><i>Paper UID:1204</i></u>





# Summary for SESL pilot



- Significant progress to towards realising the technical goal of knowledge brokering
  - Can a push model work? A “hyper”standard?
- A unique consortium from three cultures: industry, publishers and academia
  - Working together - sharing costs and risks
- Business opportunities and concerns
  - For data providers and consumers?
- Phase 2 planning is underway for 2011





# The Pistoia VSI Project

## Vocabulary Standards Initiative

Project Leads: Lee Harland and Christopher Larminie

<http://pistoiaalliance.org>



# Standardizing Drug Target Types



- Representation of a molecular drug target in structured databases is ad-hoc
  - Single protein-targets are “OK” (being linked via Entrez gene, but this is not an agreed standard)
  - Multi-protein targets, complexes, biologicals and many more are poorly described, often simply raw text
- This project will focus on industry & suppliers to describe a specification for reporting drug targets within structured content
  - Minimal cost, just FTE time required
  - This could feed into the IMI Open Pharmacology (OPS) call as an industry-publisher requirement
  - Output would be a specific set of “rules” regarding the representation of complex molecular targets
  - Aim would not be to define a list of all known targets, this would be out of scope. As will any text-mining efforts.
  - Recommendation to suppliers and industry to adopt specification along with industry-generated mappings for pre-existing targets
  - Deliverable - specification & publication
- **Could be a start to a future, wider pharmacological data standard project**
  - All databases providing pharmacological activity content delivered in a standard way
  - Could gain a quick-start building on MIABE standard



# The Pistoia Sequence Services Project

Project Lead : Simon Thornber

<http://pistoiaalliance.org>



# Sequence services Project



## *Description*

As a drive to cuts costs, encourage standards, and provide simplification it is proposed that Pistoia commission a set of secure internet hosted sequence services.


## *Benefits*

These services will ultimately provide access to public, private & commercial data & tools, that will enable scientists to search, store & analyse all their sequence based data in a single web interface.

# Current Status for sequence services

- Defined the Project Vision
- Split Vision into achievable phases of delivery
- Defined Phase 1 use cases
- Focus on Non-Functional use cases e.g. security
- Scoring criteria in final stages of drafting
- 5 Vendor presentations during May / June 2010
  - Cognizant +Eagle Genomics, ThomsonReuters, Genome Quest, & Constellation Technologies + Microsoft + AWF and the STFC.

# Sequencing service vision





# The Pistoia ELN Project

Project Lead : Richard Bolton

<http://pistoiaalliance.org>



# ELN Project Description and Benefits



## *Description*

To deliver a query service standard applicable for use with data types commonly found in electronic lab notebooks (ELN's). The initial scope will be against chemistry related ELN's but the solution should aim to be general enough that it can be applied to other scientific notebook applications.

## *Benefits*

Searching of data stored in ELN's from different vendors. Lowering the costs of using ELN data with partners and CRO's.




# Current Status for ELN



- Active Participation at biweekly meetings from GSK/AZ/Pfizer/BMS/Symyx/Edge/Accelrys
- Agreed 3 delivery phases
- Phase 1 Definition of problem space and creation of users stories.
  - Complete. User Story Document ‘published’
- Phase 2 Creation of ELN Query services definition.
  - End to end process run through by team to create a full model for two of the user stories.
  - GGA chosen to complete work. Funding agreed and approved by operations team. Work started but contract not yet in place.
- Phase 3 Creation of POC in partnership with Vendor.
  - Not yet started. Will likely require vendor partnership, budget and technology decision.

# ELN Summary



# Summary for Pistoia projects



- **SESL Biomedical Knowledge Brokering**
  - Phase 1 pilot to complete by end 2010
  - Phase 2 is planned
- **Vocabulary Standards Initiative**
  - An emerging project on Drug Targets
- **Sequence services**
  - Phase 1 nearing completion and Phase 2 planned
- **Electronic Lab Notebook**
  - Phase 1 is complete and Phase 2 is underway

# Acknowledgements



## SESL

Dietrich Rebholz Schumann, EBI  
Silvestras Kavaliauskas, EBI  
Christoph Grabmuellerm EBI  
Dominic Clark, EBI  
Mike Westaway, AZ  
Ian Dix, AZ  
Wendy Filsell, Unilever  
Ian Stott, Unilever  
Peter Woollard, GSK  
Nigel Wilkinson, Pfizer  
Catherine Marshall, Pfizer  
Michael Braxenthaler, Pfizer  
Jabe Wilson, Elsevier  
Richard O'Bierne, Oxford UP  
Richard Kidd, RSC  
Alf Eaton, Nature PG

## ELN

Richard Bolton, GSK  
David Drake, AZ  
Steve Trudel, Pfizer  
John Duncan, Pfizer  
Uwe Geissler, Novartis  
Carol McNab, BMS  
  
Vendor reps from:-  
Symyx  
Edge  
Accelrys

## Sequencing

Simon Thornber, GSK  
Cary O'Donnell, AZ  
Quan Yang, Novartis  
Monica Arenz, Novartis  
  
Steering Group:-  
Ashley George, GSK  
Tom Flores, GSK  
Martyn Wilkins  
Patrick Warren

## VSI

Lee Harland, Christopher Larminie,  
Ian Dix, Wendy Filsell, OBO PRO